Your search history is turned on.
Date: April 8, 2024 Jurisdictions: All jurisdictions
Microsoft Word - Document1 Date: April 08, 2024 324-8th Avenue SW, 8th floor Calgary AB, T2P 2Z2 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: FENNEC PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : A...
Date: April 1, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, ANDRADE, Robert, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonab...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: April 1, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
EDGAR PDF Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
EDGAR PDF Table of Contents F-1 FENNEC PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations F-5 Consolidated Statements of Shareholders Deficit F-6 Consolidated Statements of Cash Flows F-7 Notes t...
EDGAR PDF Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARK Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI in ...
EDGAR PDF Exhibit 31.2 FENNEC PHARMACEUTICALS INC. CERTIFICATION I, Robert Andrade, certify that: 1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2023 of Fennec Pharmaceuticals Inc.; 2. Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact ...
EDGAR PDF Exhibit 31.1 FENNEC PHARMACEUTICALS INC CERTIFICATION I, Rostislav Raykov, certify that: 1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2023 of Fennec Pharmaceuticals Inc.; 2. Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact...
EDGAR PDF Table of Contents 73 directly or indirectly from one or any combination of (i) real or immovable property situated in Canada, (ii) Canadian resource properties, (iii) timber resource properties, and (iv) options in respect of, or interests in, or for civil law rights in, property described in any of (i) to (iii). U.S. Holders whose common shares ...
Date: March 21, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
FORM 51-102F3 Material Change Report Item 1 Name and Address of Company Fennec Pharmaceuticals Inc. (the Company or Fennec) PO Box 13628, 68 TW Alexander Drive Research Triangle Park, North Carolina 27709, USA Item 2 Date of Material Change March March 15, 2024. Item 3 News Release News release attached hereto as Schedule A wa...